Date
- 2024 (29)
- 2023 (48)
- 2022 (26)
- 2021 (102)
- 2020 (61)
- 2019 (127)
- 2018 (41)
- 2017 (23)
- 2016 (26)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (12)
- 2008 (6)
- 2007 (12)
- 2006 (12)
- 2005 (15)
- 2004 (5)
- 2003 (3)
- 2002 (7)
- 2001 (4)
- 2000 (12)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (10)
- 1995 (2)
- 1994 (6)
- 1993 (6)
- 1991 (23)
Results for
"[search-keyword]"
Sponsor content
677 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Xenpozyme (olipudase alfa) has been approved as an enzyme replacement therapy for the treatment of noncentral nervous system manifestations of acid sphingomyelinase deficiency in paediatric and adult patients with Niemann-Pick disease (types A/B or B).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XENPOZYME olipudase alfa 4mg powder for injection vial.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd